Lightnews — Scholar-powered news

Akriti G Jain, MD, FACP

@akritigjain.bsky.social

15 followers 44 following 4 posts

Leukemia and Myeloid Disorders, Cleveland Clinic
Assistant Professor, Case Western Reserve University

Posts Replies Media Videos

Akriti G Jain, MD, FACP

@akritigjain.bsky.social

Amazing talk using analogies from football on Tackling Anemia in MF by @aarongerds.bsky.social

#mpncongress #mpnsm

November 7, 2025 at 4:18 PM

Reposted by Akriti G Jain, MD, FACP

OncLive

@onclive.bsky.social

JAK Inhibitor Selection and Sequencing Strategies Are Key in #Myelofibrosis Management @akritigjain.bsky.social #oncology

www.onclive.com/view/jak-inh...

JAK Inhibitor Selection and Sequencing Strategies Are Key in Myelofibrosis Management | OncLive

Akriti Jain, MD, discusses treatment selection and sequencing of JAK inhibitors in myelofibrosis, emerging CALR-targeted research, and defining disease modification.

www.onclive.com

November 5, 2025 at 8:15 PM

Reposted by Akriti G Jain, MD, FACP

OncLive

@onclive.bsky.social

It's time for the #FiveUnder5 🕓, your go-to roundup of the top 5 #oncology videos of the week. @washumedicine.bsky.social @akritigjain.bsky.social @clevelandclinic.bsky.social @cityofhope.bsky.social @harvardmed.bsky.social

Watch the clips: 📽️: www.onclive.com/view/five-un...

#bcsm #mmsm

October 13, 2025 at 12:57 AM

Reposted by Akriti G Jain, MD, FACP

American Society of Clinical Oncology

@ascocancer.bsky.social

THIRD! Dr. Andrew Kuykendall presents VERIFY: rusfertide vs placebo for polycythemia vera. During weeks 20-32, more patients who received rusfertide achieved a clinical response, 76.9 vs 32.9%, p<0.0001. Patients received fewer phlebotomies and had less fatigue. #ASCO25

June 1, 2025 at 7:20 PM

Akriti G Jain, MD, FACP

@akritigjain.bsky.social

Listen to our Cancer Advances Podcast on personalizing treatment of myelofibrosis related anemia!

@clevelandclinic.bsky.social

my.clevelandclinic.org/podcasts/can...